vs
ASP Isotopes Inc.（ASPI）与X4 Pharmaceuticals, Inc（XFOR）财务数据对比。点击上方公司名可切换其他公司
X4 Pharmaceuticals, Inc的季度营收约是ASP Isotopes Inc.的1.7倍（$28.8M vs $16.7M）
ASP Isotopes Inc.是一家特种材料企业，专注于高纯度定制同位素的研发与生产，产品广泛应用于核医学、靶向抗癌治疗、清洁能源及工业研究等领域，客户覆盖北美、欧洲及亚太地区。
X4制药是一家临床阶段生物技术公司，专注于开发针对存在高度未满足医疗需求的罕见免疫疾病和肿瘤适应症的新型靶向疗法，主要运营市场覆盖美国与欧洲，核心管线包括WHIM综合征候选药物及多款免疫疾病、肿瘤领域的临床和临床前资产。
ASPI vs XFOR — 直观对比
营收规模更大
XFOR
是对方的1.7倍
$16.7M
损益表 — Q4 FY2025 vs Q1 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $16.7M | $28.8M |
| 净利润 | — | $282.0K |
| 毛利率 | 12.5% | 83.6% |
| 营业利润率 | — | -32.8% |
| 净利率 | — | 1.0% |
| 营收同比 | 1295.7% | — |
| 净利润同比 | -586.8% | 100.5% |
| 每股收益（稀释后） | — | $0.04 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASPIXFOR
| Q4 25 | $16.7M | — | ||
| Q3 25 | $4.9M | — | ||
| Q1 25 | — | $28.8M | ||
| Q1 24 | — | $0 | ||
| Q3 23 | — | $0 | ||
| Q2 23 | — | $0 |
净利润ASPIXFOR
| Q4 25 | — | — | ||
| Q3 25 | $-12.9M | — | ||
| Q1 25 | — | $282.0K | ||
| Q1 24 | — | $-51.8M | ||
| Q3 23 | — | $-2.3M | ||
| Q2 23 | — | $-55.7M |
毛利率ASPIXFOR
| Q4 25 | 12.5% | — | ||
| Q3 25 | 8.7% | — | ||
| Q1 25 | — | 83.6% | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
营业利润率ASPIXFOR
| Q4 25 | — | — | ||
| Q3 25 | -306.1% | — | ||
| Q1 25 | — | -32.8% | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
净利率ASPIXFOR
| Q4 25 | — | — | ||
| Q3 25 | -263.7% | — | ||
| Q1 25 | — | 1.0% | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
每股收益（稀释后）ASPIXFOR
| Q4 25 | — | — | ||
| Q3 25 | $-0.15 | — | ||
| Q1 25 | — | $0.04 | ||
| Q1 24 | — | $-7.77 | ||
| Q3 23 | — | $-0.01 | ||
| Q2 23 | — | $-0.33 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $333.3M | $40.3M |
| 总债务越低越好 | $14.4M | $75.0M |
| 股东权益账面价值 | $204.2M | $22.9M |
| 总资产 | $498.0M | $130.0M |
| 负债/权益比越低杠杆越低 | 0.07× | 3.27× |
8季度趋势，按日历期对齐
现金及短期投资ASPIXFOR
| Q4 25 | $333.3M | — | ||
| Q3 25 | $113.9M | — | ||
| Q1 25 | — | $40.3M | ||
| Q1 24 | — | $60.5M | ||
| Q3 23 | — | $131.6M | ||
| Q2 23 | — | $136.4M |
总债务ASPIXFOR
| Q4 25 | $14.4M | — | ||
| Q3 25 | $13.9M | — | ||
| Q1 25 | — | $75.0M | ||
| Q1 24 | — | $55.0M | ||
| Q3 23 | — | $55.0M | ||
| Q2 23 | — | $32.5M |
股东权益ASPIXFOR
| Q4 25 | $204.2M | — | ||
| Q3 25 | $74.1M | — | ||
| Q1 25 | — | $22.9M | ||
| Q1 24 | — | $1.0M | ||
| Q3 23 | — | $67.6M | ||
| Q2 23 | — | $67.5M |
总资产ASPIXFOR
| Q4 25 | $498.0M | — | ||
| Q3 25 | $225.9M | — | ||
| Q1 25 | — | $130.0M | ||
| Q1 24 | — | $112.2M | ||
| Q3 23 | — | $173.3M | ||
| Q2 23 | — | $173.4M |
负债/权益比ASPIXFOR
| Q4 25 | 0.07× | — | ||
| Q3 25 | 0.19× | — | ||
| Q1 25 | — | 3.27× | ||
| Q1 24 | — | 53.09× | ||
| Q3 23 | — | 0.81× | ||
| Q2 23 | — | 0.48× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-37.8M | $-12.4M |
| 自由现金流经营现金流 - 资本支出 | $-47.4M | — |
| 自由现金流率自由现金流/营收 | -284.7% | — |
| 资本支出强度资本支出/营收 | 57.9% | 0.0% |
| 现金转化率经营现金流/净利润 | — | -43.86× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ASPIXFOR
| Q4 25 | $-37.8M | — | ||
| Q3 25 | $-8.9M | — | ||
| Q1 25 | — | $-12.4M | ||
| Q1 24 | — | $-33.6M | ||
| Q3 23 | — | $-68.8M | ||
| Q2 23 | — | $-47.9M |
自由现金流ASPIXFOR
| Q4 25 | $-47.4M | — | ||
| Q3 25 | $-12.0M | — | ||
| Q1 25 | — | — | ||
| Q1 24 | — | $-33.7M | ||
| Q3 23 | — | $-68.8M | ||
| Q2 23 | — | $-47.9M |
自由现金流率ASPIXFOR
| Q4 25 | -284.7% | — | ||
| Q3 25 | -245.5% | — | ||
| Q1 25 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
资本支出强度ASPIXFOR
| Q4 25 | 57.9% | — | ||
| Q3 25 | 64.4% | — | ||
| Q1 25 | — | 0.0% | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
现金转化率ASPIXFOR
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q1 25 | — | -43.86× | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
